NCT04023071View on ClinicalTrials.gov

FT516 in Subjects With Advanced Hematologic Malignancies

PHASE1TerminatedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

October 4, 2019

Primary Completion Date

October 23, 2023

Study Completion Date

October 23, 2023

Conditions
Acute Myelogenous LeukemiaB-cell Lymphoma
Interventions
DRUG

FT516

Experimental Interventional Therapy

DRUG

Rituximab

Monoclonal Antibody

DRUG

Obinutuzumab

Monoclonal Antibody

DRUG

Cyclophosphamide

Conditioning agent

DRUG

Fludarabine

Conditioning agent

DRUG

IL-2

Biologic response modifier

DRUG

Bendamustine

Conditioning agent

Trial Locations (7)

55455

University of Minnesota Masonic Cancer Center, Minneapolis

75390

UT Southwestern, Dallas

77030

MD Anderson Cancer Center, Houston

80045

University of Colorado, Denver, Denver

85054

Mayo Clinic, Phoenix

92037

UC San Diego, San Diego

98104

Swedish Cancer Institute, Seattle

Sponsors

Lead Sponsor

Fate Therapeutics
All Listed Sponsors
lead

Fate Therapeutics

INDUSTRY

NCT04023071 - FT516 in Subjects With Advanced Hematologic Malignancies | Biotech Hunter | Biotech Hunter